Skip to main content

Table 8 Treatment-related grade ≥ 2 AEs in ≥ 25% of patients in ≥ 1 treatment arms*

From: A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study

Characteristic Arm 1 (n = 46) Arm 2 (n = 76) Arm 3 (n = 42) Arm 4 (n = 40) Arm 5 (n = 80)
Hematologic, No. (%)
 Anemia (grades 1–2) 35 (76.1) 56 (73.7) 32 (76.2) 31 (77.5) 63 (78.8)
 Leukopenia 30 (65.2) 51 (67.1) 28 (66.7) 27 (67.5) 52 (65.0)
 Neutropenia 34 (73.9) 54 (71.1) 30 (71.4) 29 (72.5) 59 (73.8)
 Trombocytopenia 38 (82.6) 62 (81.6) 35 (83.3) 32 (80.0) 65 (81.3)
Constitutional symptoms, No. (%)
 Fatigue 41 (89.1) 67 (88.2) 37 (88.1) 35 (87.5) 69 (86.3)
 Insomnia 40 (87.0) 68 (89.5) 35 (83.3) 34 (85.0) 71 (88.8)
 Body weight loss 35 (76.1) 58 (76.3) 32 (76.2) 30 (75.0) 62 (77.5)
 Increased perspiration 39 (84.8) 61 (80.3) 34 (81.0) 32 (80.0) 65 (81.3)
Dermatologic, No. (%)
 Alopecia (partial or total) 46 (100) 76 (100) 42 (100) 40 (100) 80 (100)
 Nail changes 37 (80.4) 61 (80.3) 34 (81.0) 33 (82.5) 65 (81.3)
 Rash 14 (30.4) 23 (30.3) 13 (31.0) 13 (32.5) 27 (33.8)
Gastrointestinal, No. (%)
 Decreased appetite 40 (87.0) 67 (88.2) 37 (88.1) 35 (87.5) 71 (88.8)
 Constipation/Diarrhea 12 (26.1) 19 (25.0) 12 (28.6) 11 (27.5) 23 (28.8)
 Dispepsia 41 (89.1) 67 (88.2) 38 (90.5) 35 (87.5) 73 (91.3)
 Nausea/Vomiting 30 (65.2) 51 (67.1) 27 (64.3) 26 (65.0) 53 (66.3)
 Abdominal pain 19 (41.3) 31 (40.8) 18 (42.9) 17 (42.5) 35 (43.8)
Metabolic, No. (%)
 Hypomagnesemia 13 (28.3) 22 (28.9) 13 (31.0) 12 (30.0) 25 (31.3)
 Hyper/hyponatremia 14 (30.4) 24 (31.6) 12 (28.6) 13 (32.5) 24 (30.0)
 Hypocalcemia 11 (23.9) 17 (22.4) 10 (23.8) 9 (22.5) 20 (25.0)
 Alkaline phosphatase increased 12 (26.1) 19 (25.0) 10 (23.8) 10 (25.0) 19 (23.8)
Neuromuscular & skeletal, central nervous system, otic, ocular, No. (%)
 Peripheral neuropathy 10 (21.7) 18 (23.7) 8 (19.0) 10 (25.0) 18 (22.5)
 Arthralgia/myalgia 28 (60.9) 45 (59.2) 24 (57.1) 23 (57.5) 49 (61.3)
 Dizziness 14 (30.4) 24 (31.6) 13 (31.0) 12 (30.0) 26 (32.5)
 Memory impairment 35 (76.1) 58 (76.3) 33 (78.6) 31 (77.5) 60 (75.0)
 Ototoxicity 14 (30.4) 24 (31.6) 13 (31.0) 12 (30.0) 25 (31.3)
 Retinopathy 11 (23.9) 19 (25.0) 9 (21.4) 9 (22.5) 17 (21.3)
Urogenital, No. (%)
 Pain/difficulty urinating 12 (26.1) 18 (23.7) 11 (26.2) 9 (22.5) 19 (23.8)
 Others 14 (30.4) 23 (30.3) 14 (33.3) 13 (32.5) 25 (31.3)
  1. AEs adverse events
  2. *Chi-square criterion was applied to determine the differences between arms
  3. All differences between maintenance therapy arms 1–3 vs control arms 4 and 5 were statistically insignificant (p > 0.2)